Search results
Showing 46 to 60 of 136 results for atrial fibrillation
Evidence-based recommendations on dual-chamber pacemakers for treating symptomatic bradycardia caused by sick sinus syndrome without atrioventricular block.
This indicator covers the percentage of patients with atrial fibrillation, currently treated with an anticoagulant, who have had a review in the preceding 12 months which included: assessment of stroke/VTE risk; assessment of bleeding risk; assessment of renal function, creatinine clearance, FBC and LFTs as appropriate for their anticoagulation therapy; any adverse effects related to anticoagulation; assessment of compliance; choice of anticoagulant. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM147
ID NG196/1 Question Tests to diagnose persistent atrial fibrillation: What is the diagnostic accuracy of key index tests (such as the...
and cost effectiveness of stopping anticoagulation in people whose atrial fibrillation has resolved after ablation? Any explanatory...
Stroke and ischaemic attack: anti-platelet or anticoagulation (IND133)
This indicator covers the percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM94.
Rate-control drug treatment for people aged 75 and over with atrial fibrillation: What is the comparative effectiveness of the 3 main...
balloon cryoablation in relation to other procedures for treating atrial fibrillation. Further research should define patient selection...
View a complete list of indicators currently being developed. Our indicators measure outcomes that reflect the quality of care or processes.
from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment?...
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
Irreversible electroporation for treating liver metastases (IPG445)
Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.
View recommendations for IPG445Show all sections
Sections for IPG445
Atrial fibrillation: pulse rhythm assessment in people at risk
This indicator has been withdrawn following National Screening Committee recommendations and ongoing research.
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.